Stay updated on Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial
Sign up to get notified when there's something new on the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page.

Latest updates to the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page
- Check3 days agoChange DetectedAdded the California location under Locations. Removed the previous California Locations section and the HHS Vulnerability Disclosure; updated the page revision from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not be about the study, along with Revision: v3.3.2. Removed the previous description stating PubMed publications are automatically created and Revision: v3.2.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page no longer displays the standard government funding status notice. This change does not affect the study details or access, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedNo substantive changes to the study design, eligibility criteria, endpoints, or locations were detected between the screenshots. The updates appear to be minor formatting or metadata adjustments that do not affect the page’s purpose.SummaryDifference0.4%

- Check82 days agoChange DetectedMajor update to operating-status notice and a version bump to v3.2.0; replaces v3.1.0.SummaryDifference3%

- Check89 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reversing Therapy Resistance: Epigenetic-Immune Clinical Trial page.